Johnson & Johnson, Janssen And Changzhou Yabang-QH Pharmachem To Jointly Establish Anti-Worm Drug Base
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson, Janssen Pharmaceutica NV and Changzhou Yabang-QH Pharmachem recently began construction of their co-designed raw pharmaceutical materials base in Changzhou High-tech District. Of the total investment of about RMB 57 million, the first phase will receive a RMB 35 million capital injection. The facility, which is compliant with European and U.S. GMP, will go into production within this year. At the same time, the center will apply for Europe COS and FDA authentication with Janssen's aid. When completed, the facility will be China's largest anti-worm drug production, research and export base. Most of the expanded products will go to global high-end markets such as the U.S., Europe and Australia. (Click her for more - Chinese Language)